Glycosylated indolocarbazoles, method for obtaining same and uses thereof
View Patent ↗Glycosylated indolocarbazoles, method for obtaining same and uses thereof. This invention relates to rebeccamycin and staurosporine derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and the production of rebeccamycin and staurosporine derivatives. The invention also relates to bacterial strains that are of use for the production of rebeccamycin and staurosporine derivatives. Lastly, the rebeccamycin and staurosporine derivatives described herein are applicable to the field of human health, specifically for manufacturing drugs that are of use in the treatment of tumour, neurological and inflammatory diseases.
1. A compound with any of formulas (I) or (II)
where
R 1 , R 2 , R 3 , R 4 and R 5 are, hydrogen,
R 6 is hydroxy or hydrogen, one of R 7 and R 8 is hydrogen and the other is hydroxy, one of R 9 and R 10 is hydrogen and the other hydroxy,
R 11 is hydrogen or methyl, and R 12 is hydrogen or methyl.
2. The compound of claim 1 , selected from the group consisting of formula (III):
formula (IV):
formula (V):
formula (VI):
formula (VII):
formula (VIII):
and
formula (IX):
3. Bacterial strains derived from Streptomyces albus , characterized in that each one of said strains has additional nucleic acids which encode active enzymes for the biosynthesis of glycosylated indolocarbazoles, these enzymes not being present in Streptomyces albus , wherein said strain is selected from the group consisting of Streptomyces albus 16GNT(pRHAM), Streptomyces albus 16GNT(pLNBIV), Streptomyces albus 16GNT(pLN 2 ), and Streptomyces albus 16GNT(pLNR).
4. The bacterial strain of claim 3 , characterized in that said nucleic acids are the plasmids pKC16GNT and pRHAM, which encode active enzymes for the biosynthesis of the compounds of formula (III):
and formula (VII);
5. The bacterial strain of claim 3 , characterized in that said nucleic acids are the plasmids pKC16GNT and pLNBIV, which encode active enzymes for the biosynthesis of the compounds of formula (IV):
and formula (VIII):
6. The bacterial strain of claim 3 , characterized in that said nucleic acids are the plasmids pKC16GNT and pLN2, which encode active enzymes for the biosynthesis of the compounds of formula (V):
and formula (IX):
7. The bacterial strain of claim 3 , characterized in that said nucleic acids are the plasmids pKC16GNT and pLNR, which encode active enzymes for the biosynthesis of the compound of formula (VI):
8. A method to obtain the bacterial strains of claim 3 , which comprises the introduction of a nucleic acid in Streptomyces albus or in a strain derived from Streptomyces albus.
9. The method of claim 8 , where the introduction of a nucleic acid comprises the introduction of: (i) plasmids pKC16GNT and pRHAM in Streptomyces albus ; (ii) plasmids pKC16GNT and pLNBIV in Streptomyces albus ; or (iii) plasmids pKC16GNT and pLN2 in Streptomyces albus.
10. The method of claim 1 , where the introduction of a nucleic acid comprises the introduction of plasmids pKC16GNT and pLNR in Streptomyces albus.
11. A method for producing rebeccamycin or staurosporine derivatives according to any of formulas (I) or (II) of claim 1 , which comprises:
a) incubating a bacterial strain to produce a composition including a rebeccamycin or staurosporine derivative according to any of formulas (I) or (II) of claim 1 ; and
b) isolating the rebeccamycin or staurosporine derivative from the composition produced in step (a),
wherein the bacterial strain is derived from Streptomyces albus , characterized in that each one of said strains has additional nucleic acids which encode active enzymes for the biosynthesis of glycosylated indolocarbazoles, these enzymes not being present in Streptomyces albus , wherein said strain is selected from the group consisting of Streptomvces albus 16GNT(pRHAM), Streptomvces albus 16GNT(pLNBIV), Streptomvces albus 16GNT(pLN2), and Streptomvces albus 16GNT(pLNR.
12. A method according to claim 11 , characterized in that the rebeccamycin or staurosporine derivative is selected from the group consisting of the compound of formula (III):
formula (IV):
formula (V):
formula (VI):
formula (VII):
and formula (VIII):
and
formula (IX):
13. A pharmaceutical preparation which comprises a therapeutically effective quantity of a compound of claim 1 , or a pharmaceutically effective salt, together with one or more excipients and diluents.
14. A pharmaceutical preparation which comprises a therapeutically effective quantity of a compound of any of formulas (X) or (XI)
where
R 1 , R 2 , R 3 , R 4 , and R 5 are hydrogen,
R 6 is hydroxy or hydrogen, one of R 7 and R 8 is hydrogen and the other is hydroxy, one of R 9 and R 10 is hydrogen and the other hydroxy,
R 11 is hydrogen or methyl, and R 12 is hydrogen or methyl.
15. A pharmaceutical preparation in accordance with claim 14 , where the compound is selected from the group consisting of formula (XII)
formula (XIII)
formula (XIV)
formula (XV)
formula (XVI)
formula (XVII)
formula (XVIII)
16. A pharmaceutical preparation which comprises a therapeutically effective quantity of a compound with any of formulas (III):
(IV):
(V):
(VI):
(VII):
(VIII):
(IX):
(XII):
(XIII):
(XIV):
(XV):
(XVI):
(XVII):
or (XVIII):
or a pharmaceutically effective salt, together with one or more excipients and diluents.
17. A method of reducing kinase protein activity, said method comprising administering to a subject in need of a reduction in kinase protein activity a therapeutically effective quantity of a compound of any of formulas (III):
(IV):
(V):
(VI):
(VII):
VIII):
(IX):
(XII):
(XIII):
(XIV):
(XV):
(XVI):
(XVII):
or (XVIII):
or a pharmaceutically acceptable salt thereof.
18. The method of claim 17 , characterized in that the kinase is selected from the group consisting of kinases: AurA, AurB, Chk1, Dyrk1a, Ft13, FGFR1, HGK, Ikkb, Jak2, KDR and SYK.